Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to help adult smokers cut back or quit cigarettes.
After reviewing the scientific evidence, the agency has decided 20 ZYN nicotine pouch products can legally be sold in the US.
Nicotine pouches are a newer class of smokeless products that don’t contain tobacco. Zyn became the first FDA-authorized brand on Jan. 16.
This marketing decision from the FDA covers 2 nicotine strengths, 3 mg and 6 mg, and 10 flavors of the small tobacco-free synthetic pouches.
The U.S. Food and Drug Administration issued a rule to drastically reduce the amount of nicotine in cigarettes and other combusted tobacco products.
The proposal in the waning days of the Biden administration leaves it up to President-elect Donald Trump to finalize the effort — or scrap it.
The FDA said "an extensive scientific review" found the products were found to pose lower risks of cancer and other serious health conditions compared to cigarettes and smokeless tobacco products.
FDA authorizes Zyn nicotine pouches, citing public health benefits for adult smokers, despite concerns over flavored products' appeal to teens.
The Food and Drug Administration (FDA) announced on Thursday that it authorized the marketing of Zyn nicotine pouches but will be "closely monitoring youth use." Newsweek reached out to Zyn for comment.
On January 15, the U.S. Food and Drug Administration (FDA) issued a proposed rule that would set a maximum nicotine level in combusted cigarettes
General Practitioners Aotearoa is concerned the government is funding the products without robust scientific evidence and could cause more harm than good.